Inverness Medical Innovations extends 7.875% Senior Notes exchange offer

Inverness Medical Innovations, Inc. (NYSE: IMA) announced today that it has further extended its offer to exchange up to $100,000,000 in aggregate principal amount of 7.875% Senior Notes due 2016 (the "Notes") that have been registered under the Securities Act of 1933, as amended, for a like principal amount of its outstanding unregistered 7.875% Senior Notes due 2016, to 5:00 p.m., New York City time, on Friday, June 11, 2010, unless further extended.

The terms and conditions of the exchange offer are set forth in Inverness's prospectus dated April 21, 2010.

The exchange offer had been scheduled to expire at 5:00 p.m., New York City time, on Friday, June 4, 2010.  Inverness has been advised that, as of that time, $98,000,000 in aggregate principal amount, or approximately 98% of the aggregate principal amount, of outstanding unregistered 7.875% Senior Notes due 2016 had been validly tendered to the exchange agent by the holders thereof, including by means of guaranteed delivery.

The exchange agent for the offer is The Bank of New York Mellon Trust Company, N.A., Corporate Trust Operations, Reorganization Unit, 101 Barclay Street — 7 East, New York, NY 10286, Attn: Carolle Montreuil, (212) 815-5920.

Source:

Inverness Medical Innovations, Inc.

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.